PSTV
NASDAQ HealthcarePLUS THERAPEUTICS, Inc. - Common Stock
Biotechnology
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
๐ Market Data
| Price | $5.47 |
|---|---|
| Volume | 110,780 |
| Market Cap | 37.65M |
| Beta | 1.400 |
| RSI (14-Day) | 45.1 |
| 200-Day MA | $10.35 |
| 50-Day MA | $5.74 |
| 52-Week High | $23.50 |
| 52-Week Low | $2.90 |
| P/E Ratio | 0.25 |
| Forward P/E | -2.31 |
| Price / Book | 7.60 |
๐ฏ Investment Strategy Scores
PSTV scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (98/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (1/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find PSTV in your text
Paste any article, transcript, or post โ the tool will extract PSTV and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-06-02.